eXoZymes, Inc.
HealthcareNASDAQ:EXOZ · NASDAQ Global Market
-$0.60 today
Vol 0.01M · Avg 0.01M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-269.6%
avg 0.4%
ROIC
-203.1%
avg -101.4%
ROA
-153.4%
avg -71.8%
Analysis
ROA is currently the strongest return metric at -153.4% versus its period average of -71.8%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Michael Heltzen | President & Chief Executive Officer | $608,333.00 | — | 45 | $10,628.80 | 0.13% |
Damien A. Perriman | Chief Commercial Officer | $310,762.00 | — | 49 | $62,759.00 | 0.74% |
Tyler Korman | Co-Founder & Chief Scientific Officer | $260,417.00 | — | 47 | $729,123.00 | 8.60% |
Fouad Nawaz | Vice President of Finance | $258,333.00 | — | 40 | $9,488.00 | 0.11% |
Paul Opgenorth | Co-Founder & Vice President of Development | $257,292.00 | — | 43 | $645,149.00 | 7.61% |
James U. Bowie | Founder & Independent Director | — | — | 64 | — | — |
Lasse H. Gorlitz | Vice President of Communications | — | — | — | — | — |
Michael Burns | Executive Vice President of Energy Transition | — | — | — | $10,628.80 | 0.13% |
Amy Lunzer | Chief of Staff | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
1
$10,628.80
Sells
2
$15,424.20
Net Sentiment
$4,795.40
Net selling
Most Active
Korman Tyler Paz
2 transactions
| Date | Insider | Type | Shares | Price | Value | |
|---|---|---|---|---|---|---|
| Apr 9, 2026 | Korman Tyler Paz Direct | Sell | 750 | $10.53 | $7,893.75 | |
| Apr 8, 2026 | Korman Tyler Paz Direct | Sell | 750 | $10.04 | $7,530.45 | |
| Jul 2, 2025 | Heltzen Michael Direct | Buy | 1.0K | $10.22 | $10,628.80 |
Analysis
Insiders reported 1 buys worth $10,628.80 and 2 sells worth $15,424.20 over the last 12 months. That adds up to net selling of $4,795.40. Korman Tyler Paz was the most active insider with 2 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A — |
| Revenue | N/A | N/A | N/A | N/A — |
| Net Income | N/A | N/A | N/A | N/A — |
| EBIT | N/A | N/A | N/A | N/A — |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Peer companies in the same sector
Greenwich LifeSciences, Inc.
NASDAQ:GLSI
$353.16M
Surrozen, Inc.
NASDAQ:SRZN
$174.90M
Cognition Therapeutics, Inc.
NASDAQ:CGTX
$89.03M
Oncolytics Biotech Inc.
NASDAQ:ONCY
$80.59M
Tiziana Life Sciences Ltd
NASDAQ:TLSA
$65.37M
Instil Bio, Inc.
NASDAQ:TIL
$53.71M
Estrella Immunopharma, Inc.
ESLA
$45.62M
Tevogen Bio Holdings Inc.
TVGN
$43.84M
Atossa Therapeutics, Inc.
ATOS
$21.18M
Anebulo Pharmaceuticals, Inc.
ANEB
$19.37M
Who manages EXOZ?
eXoZymes, Inc. (EXOZ) lists 9 active executives. The top listed executive is Paul Opgenorth, Co-Founder & Vice President of Development.
Are EXOZ insiders buying or selling?
Recent insider activity shows net buying of $4.63M.
Explore More
Continue the stock analysis
Jump to another research area for this company.